GAMMAGARD S/D IMMUNE GLOBULIN I.V. 2.5 G

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

IMMUNOGLOBULIN NORMAL HUMAN 50 MG/ML

Disponível em:

TEVA MEDICAL MARKETING LTD.

Código ATC:

J06BA02

Forma farmacêutica:

POWDER FOR SOLUTION FOR INJECTION

Via de administração:

I.V

Fabricado por:

BAXTER HEALTHCARE CORPORATION, USA

Grupo terapêutico:

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM.

Indicações terapêuticas:

Replacement therapy in:• primary immunodeficiency syndromes (PID) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - Wiskott Aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (CLL) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital AIDS and recurrent infections.Immunomodulation• idiopathic thrombocytopenic purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• Guillain Barr? syndrome. In this case GAMMAGARD S/D (Solvent/Detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• Kawasaki disease.Allogeneic bone marrow transplantation

Data de autorização:

2010-07-01